康泰生物终止对外投资设立合资公司计划

Core Viewpoint - The company has decided to terminate its plans for establishing a joint venture due to significant changes in the market environment and high investment risks in the vaccine industry [1] Group 1: Company Decisions - The company's board of directors approved the proposal to terminate the investment in a joint venture during the eighth board meeting on February 6, 2026 [1] - The decision was made after the board assessed the severe downward pressure on the vaccine industry and the associated high risks of new investments [1] - The company will authorize management to finalize and sign the termination agreement with partners, relieving all parties from related obligations and responsibilities upon termination [1] Group 2: Market Context - The termination of the investment is aimed at responding to market changes and controlling investment risks [1] - The company anticipates that this decision will not have a significant adverse impact on its existing business and financial condition [1]